MIL:ARBS

Arterra Bioscience · MIL · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 12:44 UTC

Last close

n/aEUR

Market data

10.1xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
43.1%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
33.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
4.2%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Five bars, one line

lens 7 of 9

1.37x

1.69x

2.30x

0.43x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.37x
Its own average over 9 years, 3.4M.
Profit1.69x
Its own average over 9 years, 1.2M.
Free cash flow2.30x
Its own average over 9 years, 668.5K.
Debt0.43x
Its own average over 9 years, 604.5K.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 2.30 times.

Sales is 1.37 times its own 9-year average; Profit is 1.69 times its own 9-year average; Free cash flow is 2.30 times its own 9-year average; Debt is 0.43 times its own 9-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 9-year average1.37
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Profit against its own 9-year average1.69
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Free cash flow against its own 9-year average2.30
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Debt against its own 9-year average0.43
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
EUR